Searched for
BAVLA FACILITY
New Century Sofa India inks 2.72 lakh sq ft lease at IndoSpace Industrial ParkIndoSpace has leased 2.72 lakh sq ft to New Century Sofa India at its Oragadam II Industrial Park. This deal underscores IndoSpace's accele...- Inox Solar inks pact with LONGi to supply 5 GW of solar modulesInox Solar has signed an initial agreement with LONGi for a significant solar module supply. This partnership will bring up to 5 GW of sola...
- China's LONGi Green Energy to source Rs 7,000 crore modules from Inox SolarInox Solar, part of INOXGFL Group, has secured a significant ₹7,000 crore contract with China's LONGi Green Energy Technology Co. Ltd. for ...
- Inox Solar commences production at solar module manufacturing facility in GujaratInox Clean Energy, a subsidiary of Inox Solar, has commenced production at its new solar module manufacturing facility in Bavla, Ahmedabad,...
- IndoSpace leases warehouse in Gujarat’s Bavla to 3PL co Robinsons Global LogisticsRobinsons Global Logistics Solutions has signed a five-year lease with IndoSpace for a 30,000 sq ft sustainable Grade-A warehouse in Bavla,...
- Union minister Amit Shah inaugurates flyover, health centre in his constituency in GujaratThis six-lane flyover has been built by the Ahmedabad Urban Development Authority (AUDA) at a cost of Rs 73 crore to ease traffic congestio...
- Dishman Carbogen back on investor radar amid hopes of recoveryAfter reporting a drop in revenue and a net loss for FY21, the company is expected to benefit from high potential new molecules that are cu...
- Arvind Ltd launches its Rs 350 crore garmenting hub in GujaratThe $1.7 billion textile-to-retail conglomerate has set up 2 manufacturing facilities in the region and said a third facility will commence...
- Dishman Pharma rallies after receiving EIR for Bavla facilityOn the BSE, 1 lakh shares were traded on the counter so far as against the average daily volumes of 1.49 lakh shares in the past two weeks.
- Dishman gets licence from Johnson & Johnson to produce TB drug raw materialDishman Pharmaceuticals and Chemicals today said it has received a licence from Johnson & Johnson to manufacture raw material for a tubercu...
- Dishman Pharma hits 52-week high as drug maker gets licence to manufacture TB medicineDishman Pharmaceuticals and Chemicals surged 16.22 per cent to close at 306.95. The stock closed at a fresh 52-week high on Wednesday.
- Dishman Pharma rallies 3% on debt reduction plansDishman rallied as much as 3% on reports that the company is in talks to sell its 175 hectares of land in Gujarat to Nirma to cut its debt.
- Pradip Overseas Limited plans industrial hub in GujaratTextile maker Pradip Overseas Limited announced its plans to set up an industrial hub spread over 18,00,000 sq. yards at Bavla near Ahmedab...
- Dishman revives engineering SEZ project, land acquisition to complete in one yearAhmedabad-based Dishman group will acquire 100 hectares land and revive its engineering SEZ project, it scrapped two years ago.
- World's first carbon foam battery unit comes up in GujaratThe promoters of furnace maker Electrotherm acquired the US battery maker, Firefly Energy, in October 2010 along with its patented technolo...
- Jordan's Hikma in talks to buy 30% in Unimark RemediesJordan-based Hikma Pharmaceuticals is in negotiations to buy 30% stake in Mumbai-based Unimark Remedies, two people familiar with the matte...
- Dishman to chase high-potency therapiesDishman Pharmaceuticals Ltd, will now focus on the high-potency therapies like steroids, hormones, isotopes and cytotoxics.
- Dishman to invest Rs 500 cr in two SEZsDrug maker Dishman Pharmaceuticals on Thursday said it will invest Rs 500 crore in two special economic zones and has completed acquisition...
- Dishman Pharma rises 10% on expansion plansShares of Dishman Pharmaceuticals & Chemicals surged nearly 10 per cent after it announced plans to invest Rs 5 billion in two SEZs and ent...
- Prabhudas puts outperformer on Dishman Pharma; target Rs 449Prabhudas Lilladher has reiterated ‘outperformer’ rating on Dishman Pharmaceuticals for a price target of Rs 449 (15x FY10 earnings), an im...
Load More
